Format

Send to

Choose Destination
See comment in PubMed Commons below
Cochrane Database Syst Rev. 2000;(4):CD002174.

Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis.

Author information

1
Aintree Chest Centre, University Hospital, Aintree, Aintree Chest Centre, University Hospital Aintree, Lower Lane, Liverpool, Merseyside, UK, L9 7AL. j.corless@bigfoot.com

Abstract

BACKGROUND:

Leukotriene receptor antagonists are a new class of drug that were initially identified for use in asthma. As they have an effect on neutrophil mediated inflammation, they may be of benefit in bronchiectasis.

OBJECTIVES:

To determine whether leukotriene receptor antagonists have any additive benefit over and above conventional treatment for bronchiectasis (usually consisting of antibiotics and postural drainage).

SEARCH STRATEGY:

The Cochrane Airways Group clinical trials register derived from MEDLINE, EMBASE and hand searching of major journals was searched using the terms:Bronchiec* AND leukotrien* OR anti-leuk* OR cysteinyl, Bronchiec* AND monteluk*, Bronchiec* AND zafirluk*

SELECTION CRITERIA:

Only randomised, controlled trials were considered

DATA COLLECTION AND ANALYSIS:

The results of searches were analysed by both authors

MAIN RESULTS:

No randomised, controlled trials were identified

REVIEWER'S CONCLUSIONS:

Further research is required to establish any benefit from the use of leukotriene antagonists in bronchiectasis.

PMID:
11034744
DOI:
10.1002/14651858.CD002174
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center